Our Mission: Highlighting Innovations by showcasing breakthroughs in cancer research, including diagnostic tools, therapies, and preventive measures.

Clinical Research

Explore the latest developments in cellular research, including stem cell therapy, regenerative medicine, and innovative approaches to treating diseases at the cellular level.

Target Edonc

The Targeted Pulse: Discover the FDAÕs Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers

The subcutaneous formulation of nivolumab (Opdivo Qvantig) received FDA approval for all previously approved adult solid tumor indications as monotherapy, maintenance therapy, or in combination with chemotherapy or cabozantinib (Cabometyx). Data from the phase 3 CheckMate-67T study (NCT04810078) provided support for this approval. In the trial, subcutaneous nivolumab was compared with its intravenous formulation.

Read More »
error: Content is protected !!